Browsing Tag
clinical trials
131 posts
What is gold nanorod therapy and how does Sona Nanotech plan to use it to treat late-stage melanoma patients?
Sona Nanotech’s gold nanorod cancer therapy is heading to human trials. Learn how its CTAB-free Targeted Hyperthermia Therapy works and what’s next for melanoma care.
Bone Biologics prices $5m equity and warrant offering to accelerate spinal fusion trial development
Bone Biologics Corporation has priced a $5 million public offering to advance its spine fusion therapy trials and intellectual property. Learn what this means for investors.
Sona Nanotech set to launch first human trial of its gold nanoparticle cancer therapy
Sona Nanotech receives ethics approval to begin first-in-human melanoma trial using gold nanorod-based hyperthermia therapy. Patient dosing to start soon.
Metabolics Pharma’s ENT-03 shows promising Phase 1a data in obese and type 2 diabetic patients at ADA 2025
Metabolics Pharma’s ENT-03 shows Phase 1a success in obese and diabetic subjects, with plans for Phase 1b in late 2025. Learn about its brain-based mechanism.
FDA extends deadline for Incyte’s Opzelura cream review in pediatric eczema following submission of new manufacturing data
Incyte (NASDAQ: INCY) faces FDA review delay for Opzelura® cream in children aged 2–11 with eczema, following CMC data submission. Decision now due September 2025.
Genentech’s Lunsumio and Polivy combination triples remission in relapsed large B-cell lymphoma
Genentech's chemo-free Lunsumio and Polivy combo tripled remission time in relapsed B-cell lymphoma, signaling a shift toward outpatient oncology treatment.
How Novo Nordisk is building a post-semaglutide strategy: Inside its metabolic pipeline and innovation bets
Novo Nordisk pivots beyond semaglutide with amycretin, CagriSema, and oral GLP-1 therapies. See how it’s building its next-generation obesity drug platform.
Will CABOMETYX secure EU approval for advanced neuroendocrine tumors after CHMP’s positive opinion?
Ipsen’s CABOMETYX receives EMA's CHMP backing for advanced neuroendocrine tumors; EU approval expected in 2025 following FDA nod.
Candid Therapeutics launches first-in-class T-cell engager trials across five autoimmune diseases
Candid Therapeutics begins Phase 1 trials of BCMA and CD20 T-cell engagers across five autoimmune diseases; institutional interest builds around TCE approach.
Semaglutide shows significant vascular benefits in PAD patients with type 2 diabetes, STRIDE trial confirms
Semaglutide improves walking capacity and reduces disease progression in PAD patients with type 2 diabetes, STRIDE trial results reveal at ADA 2025.